Development of oseltamivir phosphonate congeners as anti-influenza agents

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8657-8670

  Cheng, Ting Jen R ^a   Weinheimer, Steven ^b   Tarbet, E Bart ^c   Jan, Jia Tsrong ^a   Cheng, Yih Shyun E ^a   Shie, Jiun Jie ^a   Chen, Chun Lin ^d   Chen, Chih An ^d   Hsieh, Wei Che ^d   Huang, Pei Wei ^e   Lin, Wen Hao ^e   Wang, Shi Yun ^a   Fang, Jim Min ^a,d   Hu, Oliver Yoa Pu ^e   Wong, Chi Huey ^a  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b TaiMed Biologics   (United States)

^c UTAH STATE UNIVERSITY   (United States)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GUANIDINO TAMIPHOSPHOR; GUANIDINO TAMIPHOSPHOR MONOETHYL ESTER DERIVATIVE; OSELTAMIVIR; OSELTAMIVIR PHOSPHONATE CONGENER; PLASMA PROTEIN; TAMIPHOSPHOR; TAMIPHOSPHOR MONOETHYL ESTER DERIVATIVE; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG PROTEIN BINDING; DRUG STABILITY; FEMALE; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS; LIVER MICROSOME; MOUSE; NONHUMAN; STOMACH JUICE; VIRUS REPLICATION; VIRUS STRAIN;

ACETAMIDES; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CYCLOHEXENES; CYTOPATHOGENIC EFFECT, VIRAL; DOGS; DRUG RESISTANCE, VIRAL; DRUG STABILITY; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZAVIRUS A; INFLUENZAVIRUS B; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PROTEIN BINDING; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867750793     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3008486     Document Type: Article

References (39)

1. Schmidt, A. C. Antiviral therapy for influenza: a clinical and economic comparative review Drugs 2004, 64, 2031-2046
2. Moscona, A. Neuraminidase inhibitors for influenza N. Engl. J. Med. 2005, 353, 1363-1373
3. De Clercq, E. Antiviral agents active against influenza A viruses Nat. Rev. Drug Discovery 2006, 5, 1015-1025
4. Woods, J. M.; Bethell, R. C.; Coates, J. A.; Healy, N.; Hiscox, S. A.; Pearson, B. A.; Ryan, D. M.; Ticehurst, J.; Tilling, J.; Walcott, S. M. 4-Guanidino-2,4-dideoxy-2,3-dehydro- N -acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro Antimicrob. Agents Chemother. 1993, 37, 1473-1479
5. Dunn, C. J.; Goa, K. L. Zanamivir: a review of its use in influenza Drugs 1999, 58, 761-784
6. Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors J. Med. Chem. 1998, 41, 2451-2460
7. McClellan, K.; Perry, C. M. Oseltamivir: a review of its use in influenza Drugs 2001, 61, 263-283
8. Sidwell, R. W.; Smee, D. F. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza Expert Opin. Invest. Drugs 2002, 11, 859-869
9. Jain, S.; Fry, A. M. Peramivir: another tool for influenza treatment? Clin. Infect. Dis. 2011, 52, 707-709
10. Kubo, S.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Yamashita, M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob. Agents Chemother. 2010, 54, 1256-1264
11. Ikematsu, H.; Kawai, N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza Expert Rev. Anti-Infect. Ther. 2011, 9, 851-857
12. Shie, J.-J.; Fang, J.-M.; Wang, S.-Y.; Tsai, K.-C.; Cheng, Y.-S. E.; Yang, A.-S.; Hsiao, S.-C.; Su, C.-Y.; Wong, C.-H. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity J. Am. Chem. Soc. 2007, 129, 11892-11893
13. Shie, J.-J.; Fang, J.-M.; Wong, C.-H. A concise and flexible synthesis of the potent anti-influenza agents tamiflu and tamiphosphor Angew. Chem., Int. Ed. 2008, 47, 5788-5791
14. von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 1993, 363, 418-423
15. White, C. L.; Janakiraman, M. N.; Laver, G. W.; Philippon, C.; Vasella, A.; Air, G. M.; Luo, M. A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies J. Mol. Biol. 1995, 245, 623-634
16. Carbain, B.; Martin, S. R.; Collins, P. J.; Hitchcock, P. B.; Streicher, H. Galactose-conjugates of the oseltamivir pharmacophore - new tools for the characterization of influenza virus neuraminidases Org. Biomol. Chem. 2009, 7, 2570-2575
17. Demmer, C. S.; Krogsgaard-Larsen, N.; Bunch, L. Review on modern advances of chemical methods for the introduction of a phosphonic acid group Chem. Rev. 2011, 111, 7981-8006
18. Schug, K. A.; Lindner, W. Noncovalent binding between guanidinium and anionic groups: focus on biological- and synthetic-based arginine/guanidinium interactions with phosph[on]ate and sulf[on]ate residues Chem. Rev. 2005, 105, 67-114
19. Proudfoot, J. R. The evolution of synthetic oral drug properties Bioorg. Med. Chem. Lett. 2005, 15, 1087-1090
20. Straub, J. O. An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions Ecotox. Environ. Safety 2009, 72, 1625
21. Miller, J. M.; Dahan, A.; Gupta, D.; Varghese, S.; Amidon, G. L. Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir Mol. Pharm. 2010, 7, 1223-1234
22. Liu, K.-C.; Lee, P.-S.; Wang, S.-Y.; Cheng, Y.-S. E.; Fang, J.-M.; Wong, C.-H. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir Bioorg. Med. Chem. 2011, 19, 4796-4802
23. Li, W.; Escarpe, P. A.; Eisenberg, E. J.; Cundy, K. C.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lew, W.; Williams, M.; Zhang, L.; Kim, C. U.; Bischofberger, N.; Chen, M. S.; Mendel, D. B. Identification of GS4104 as an orally bioavilable prodrug of the influenza virus neuraminidase inhibitor GS4071 Antimicrob. Agents Chemother. 1998, 42, 647-653
24. Koyama, K.; Takahashi, M.; Oitate, M.; Nakai, N; Takakusa, H.; Miura, S.-i.; Okazaki, O. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract Antimicrob. Agents Chemother. 2009, 53, 4845-4851
25. Xie, G.; Nie, T.; Mackenzie, G. G.; Sun, Y.; Huang, L.; Ouyang, N.; Alsont, N.; Zhu, C.; Murray, O. T.; Constantinides, P. P.; Kopelovich, L.; Rigas, B. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine Br. J. Pharmacol. 2012, 165, 2152-2166
26. Widmer, N.; Meylan, P.; Ivanyuk, A.; Aouri, M.; Decosterd, L. A.; Buclin, T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics Clin. Pharmacokinet. 2010, 49, 741-765
27. Cass, L. M.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled, or intranasal administration to healthy volunteers Clin. Pharmacol. 1999, 36 (Suppl) 1-11
28. Krise, J. P.; Stella, V. J. Prodrugs of phosphates, phosphonates, and phosphinates Adv. Drug Delivery Rev. 1996, 19, 287-310
29. Sun, J.; Miller, J. M.; Beig, A.; Rozen, L.; Amidon, G. L.; Dahan, A. Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality Expert Opin. Drug Metab. Toxicol. 2011, 7, 313-323
30. Boonyapiwat, B.; Sarisuta, N.; Kunastitchai, S. Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir Curr. Drug Delivery 2011, 8, 392-397
31. Varghese Gupta, S.; Gupta, D.; Sun, J.; Dahan, A.; Tsume, Y.; Hilfinger, J.; Lee, K.-D.; Amidon, G. L. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach Mol. Pharm. 2011, 8, 2358-2367
32. Neumann, G.; Watanabe, T.; Ito, H.; Watanabe, S.; Goto, H.; Gao, P.; Hughes, M.; Perez, D. R.; Donis, R.; Hoffmann, E.; Hobom, G.; Kawaoka, Y. Generation of influenza A viruses entirely from cloned cDNAs Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9345-9350
33. Fodor, E.; Devenish, L.; Engelhardt, O. G.; Palese, P.; Brownlee, G. G.; García-Sastre, A. Rescue of influenza A virus from recombinant DNA J. Virol. 1999, 73, 9679-9682
34. Reed, L. J.; Müench, H. A simple method of estimating fifty percent endpoints Am. J. Hyg. 1938, 27, 493-497
35. Burleson, F. G.; Chambers, T. M.; Wiedbrauk, D. L. Virology, a Laboratory Manual; Academic Press: San Diego, CA, 1992.
36. National Research Council. Guide for the care and use of laboratory animals; National Academy Press: Washington, DC, 1996.
37. United States Pharmacopeia and National Formulary, 34 th ed.; United States Pharmacopeial Convention Inc.: Rockville, MD, 2011.
38. Guidance for Industry: Drug interaction studies: study design, data analysis and implications for dosing and labeling. http://www.fda.gov/cder. Draft published in September 2006 (accessed Oct 6, 2006).
39. Waters, N. J.; Jones, R.; Williams, G.; Sohal, B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding J. Pharm. Sci. 2008, 97, 4586-4595